茯苓多糖对急性胰腺炎大鼠肠道屏障功能损伤和炎性反应的作用

摘要

目的：探究茯苓多糖对急性胰腺炎(AP)大鼠肠道屏障功能损伤和炎性反应的作用。方法将60只大鼠随机分为假手术组、AP组、AP+低剂量茯苓多糖组、AP+中剂量茯苓多糖组和AP+高剂量茯苓多糖组，每组12只。AP组大鼠腹腔注射50 g/kg雨蛙素，给药组在AP组大鼠造模前分别灌胃给予50 mg/kg、100 mg/kg、200 mg/kg茯苓多糖。模型构建12 h后，检测大鼠腹水量、血清淀粉酶和脂肪酶含量；检测大鼠小肠黏膜厚度、绒毛高度和病理学评分；RT-PCR检测肿瘤坏死因子α(TNF-α)水平，ELISA检测TNF-α、白介素-1β(IL-1β)、IL-6水平；Western blot检测JAK2和STAT3的表达。结果实验发现，与AP组相比，AP+低剂量茯苓多糖组、AP+中剂量茯苓多糖组和AP+高剂量茯苓多糖组茯苓多糖均可显著减少AP大鼠腹水量、血清淀粉酶和脂肪酶含量；增加小肠黏膜厚度和绒毛高度，减少上皮损伤；降低TNF-α，IL-1β和IL-6水平；抑制JAK2，STAT3蛋白磷酸化；且以上作用均呈现明显量效关系。结论茯苓多糖可减轻AP大鼠肠道屏障功能损伤和炎性反应，且可能与抑制JAK2/STAT3通路相关。%Objective To explore the effects of pachymaran on intestinal barrier function damage and inflam-mation in rats with acute pancreatitis. Methods Sixty rats were randomly divided into 5 groups including the sham group, AP group, low-dose pachymaran group, medium-dose pachymaran group and high-dose pachymaran group, with twelve rats in each group. AP group rats received intraperitoneal injection of 50 mg/kg cerulein. The low-dose, medi-um-dose and high-dose pachymaran group were given intragastric administration of 50 mg/kg, 100 mg/kg and 200 mg/kg pachymaran respectively before model construction of AP group. After twelve hours, the contents of the ascitic fluid, am-ylase and lipase were detected in rats with AP. The small intestinal mucosal thickness, villus height and epithelial dam-age index were detected in rats with AP. The levels of tumor necrosis factorα(TNF-α) were determined by RT-PCR, and the TNF-α, interleukins-1β (IL-1β) and IL-6 levels were determined by ELISA. The expressions of JAK2 and STAT3 proteins were determined by western blot. Results Compared to the AP group, different doses of pachymaran (low-dose, medium-dose and high-dose pachymaran group) reduced the contents of ascitic fluid, amylase and lipase, ele-vated the small intestinal mucosal thickness and villus height, reduced the epithelial damage index, decreased the levels of TNF-α, IL-1βand IL-6, and inhibited the expression of p-JAK2 and p-STAT3, all in a dose-dependent manner (P<0.01). Conclusion Pachymaran ameliorates the intestinal barrier function damage and inflammation in rats with AP, which may be associated with the inhibition of JAK2/STAT3 pathway.